- Thursday, September 21, 2023
8:00 AM – 8:15 AM ET
Welcome
8:00 AM – 8:15 AM ET
WelcomeCo-Chair: – University of California, Los Angeles
Co-Chair: – Abramson Cancer Center, Hospital of the University of Pennsylvania
Edward B. Garon, MD, MS – University of California, Los Angeles ### 758743###Co-Chair###Professor###University of California, Los Angeles###Co-Chair: – University of California, Los Angeles
### @@@ Corey J. Langer, MD, FACP (he/him/his) – Abramson Cancer Center, Hospital of the University of Pennsylvania ### 758413###Co-Chair###Director of Thoracic Oncology###Abramson Cancer Center, Hospital of the University of Pennsylvania###Co-Chair: – Abramson Cancer Center, Hospital of the University of Pennsylvania
### he/him/his8:15 AM – 9:00 AM ET
Session 1: Birdseye View of the Current Tretatment Landscape in Metastatic NSCLC without Actionable Mutations
8:15 AM – 9:00 AM ET
Session 1: Birdseye View of the Current Tretatment Landscape in Metastatic NSCLC without Actionable MutationsPresenter: – Cedars Sinai Medical Center
Karen Reckamp, MD – Cedars Sinai Medical Center ### 799344###Presenter###Professor###Cedars Sinai Medical Center###Presenter: – Cedars Sinai Medical Center
###
9:00 AM – 9:45 AM ET
Session 2: Sensitizing and Atypical EGFR Mutations
9:00 AM – 9:45 AM ET
Session 2: Sensitizing and Atypical EGFR MutationsPresenter: – Memorial Sloan Kettering Cancer Center
Gregory J. Riely, MD, PhD – Memorial Sloan Kettering Cancer Center ### 758419###Presenter###Member###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
###
9:45 AM – 9:50 AM ET
Exhibit Hall
9:45 AM – 9:50 AM ET
Break
9:50 AM – 10:50 AM ET
Non-CME Innovation Theater
9:50 AM – 10:50 AM ET
Non-CME Innovation Theater - Sponsored by AstraZeneca
10:50 AM – 11:00 AM ET
Exhibit Hall
10:50 AM – 11:00 AM ET
Exhibit Hall
11:00 AM – 11:45 AM ET
Session 3: EGFR: The Challenge of Primary and Secondary Resistance
11:00 AM – 11:45 AM ET
Session 3: EGFR: The Challenge of Primary and Secondary ResistancePresenter: – Memorial Sloan Kettering Cancer Center
Helena Yu, MD – Memorial Sloan Kettering Cancer Center ### 1345377###Presenter###Associate Attending###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
###
11:45 AM – 12:00 PM ET
Session 4: Debate: Alectinib vs Lorlatinib in ALK Positive
11:45 AM – 12:00 PM ET
Session 4: Debate: Alectinib vs Lorlatinib in ALK Positive - LorlatinibDebate Speaker: – University of California Irvine
Misako Nagasaka, MD, PhD – University of California Irvine ### 2123554###Debate Speaker###Associate Clinical Profssore###University of California Irvine###Debate Speaker: – University of California Irvine
###
12:00 PM – 12:15 PM ET
Session 4: Debate: Alectinib vs Lorlatinib in ALK Positive
12:00 PM – 12:15 PM ET
Session 4: Debate: Alectinib vs Lorlatinib in ALK Positive - AlectinibDebate Speaker: – Emory University
Ticiana Leal, MD (she/her/hers) – Emory University ### 1778151###Debate Speaker###Associate Professor, Thoracic Medical Oncology Program###Emory University###Debate Speaker: – Emory University
### she/her/hers
12:15 PM – 12:30 PM ET
Session 4: Debate: Alectinib vs Lorlatinib in ALK Positive
12:15 PM – 12:30 PM ET
Q&A PanelPanelist: – Emory University
Panelist: – University of California Irvine
Ticiana Leal, MD (she/her/hers) – Emory University ### 1778151###Panelist###Associate Professor, Thoracic Medical Oncology Program###Emory University###Panelist: – Emory University
### she/her/hers @@@ Misako Nagasaka, MD, PhD – University of California Irvine ### 2123554###Panelist###Associate Clinical Profssore###University of California Irvine###Panelist: – University of California Irvine
### 12:30 PM – 12:35 PM ET
Exhibit Hall
12:30 PM – 12:35 PM ET
Break
12:35 PM – 1:35 PM ET
Non-CME Innovation Theater
12:35 PM – 1:35 PM ET
Non-CME Innovation Theater - Sponsored by Sanofi
1:35 PM – 2:20 PM ET
Session 5: Special Topic – Unique Immune Combinations with CPIs
1:35 PM – 2:20 PM ET
Session 5: Unique Immune Combinations with CPIsPresenter: – Fox Chase Cancer Center
Hossein Borghaei, DO, MS – Fox Chase Cancer Center ### 2014938###Presenter###Professor and Chief, Thoracic Oncology###Fox Chase Cancer Center###Presenter: – Fox Chase Cancer Center
###
2:20 PM – 3:05 PM ET
Session 6: Advancing the Management of NSCLC: A Focus on Emerging Therapies
2:20 PM – 3:05 PM ET
Session 6: Advancing the Management of NSCLC: A Focus on Emerging TherapiesPresenter: – Emory University
Ticiana Leal, MD (she/her/hers) – Emory University ### 1778151###Presenter###Associate Professor, Thoracic Medical Oncology Program###Emory University###Presenter: – Emory University
### she/her/hers
3:05 PM – 3:35 PM ET
Exhibit Hall
3:05 PM – 3:35 PM ET
Exhibit Hall
3:35 PM – 4:20 PM ET
Session 7: The Era of ADCs in the Treatment of NSCLC Part 1: Class Overview and Specifics of TROP2, HER3, c-MET, and CEACAM5 Investigational ADCs
3:35 PM – 4:20 PM ET
Session 7: The Era of ADCs in the Treatment of NSCLC Part 1: Class Overview and Specifics of TROP2, HER3, c-MET, and CEACAM5 Investigational ADCs
Barbara Melosky, MD – Bc Cancer ### 1961092###Presenter###Medical Oncologist###Bc Cancer###Presenter: – Bc Cancer
###
4:20 PM – 5:05 PM ET
Session 8: HER2 and the Emerging Roles of HER Family ADCs
4:20 PM – 5:05 PM ET
Session 8: HER2 and the Emerging Roles of HER Family ADCsPresenter: – Rush University
Helen J. Ross, MD (she/her/hers) – Rush University ### 758420###Presenter###Thoracic Medical Oncologist, Director of Research and Clinical Trials###Rush University###Presenter: – Rush University
### she/her/hers
